School of Pharmacy, Fujian Medical University, Fuzhou, Fujian, China.
Department of Pharmacy, Fujian Maternity and Child Health Hospital, College of Clinical Medicine for Obstetrics & Gynecology and Pediatrics, Fujian Medical University, 18 Daoshan Road, Fuzhou, Fujian, 350001, China.
J Assist Reprod Genet. 2024 Mar;41(3):551-561. doi: 10.1007/s10815-024-03021-z. Epub 2024 Jan 11.
Previous studies had demonstrated that high-mobility group box 1 (HMGB1) levels were elevated in preeclampsia (PE). However, the conclusion remains controversial. This study aimed to investigate the association between blood and placenta HMGB1 levels and PE in pregnant women.
After a systematic literature search, eligible literature was screened according to inclusion and exclusion criteria. Data extraction and quality assessment were performed independently by two reviewers. The extracted data were analyzed using Review Manager 5.4 and STATA 12.0 software. Subgroup analysis and meta-regression analysis were conducted to find potential sources of heterogeneity.
Twelve studies were included, with a total of 1145 participants. Compared with normal pregnancies, pregnant women with PE had significantly higher blood HMGB1 levels (SMD = 1.34, 95% CI: 0.72-1.95, p < 0.0001). Similarly, the expression of placental HMGB1 in PE was higher than that in normal controls by using Western blot (MD = 0.37, 95% CI: 0.27-0.47, p < 0.00001) or immunohistochemistry (OR = 6.36, 95% CI: 1.48-27.25, p = 0.01). In addition, the blood HMGB1 levels were positively correlated with the severity of PE, with higher blood HMGB1 levels in severe PE than those in mild PE (SMD = 3.35, 95% CI: 0.63-6.06, p = 0.02). The subgroup analysis indicated a close association of blood HMGB1 with PE in the Asian group, but not in the European group.
Both blood and placental HMGB1 levels in patients with PE were significantly elevated, and higher blood HMGB1 levels indicated a more serious disease condition, suggesting that higher levels of HMGB1 were associated with the risk of PE.
先前的研究表明,高迁移率族蛋白 B1(HMGB1)水平在子痫前期(PE)中升高。然而,结论仍存在争议。本研究旨在探讨孕妇血液和胎盘 HMGB1 水平与 PE 之间的关系。
经过系统的文献检索,根据纳入和排除标准筛选合格文献。两名评审员独立进行数据提取和质量评估。使用 Review Manager 5.4 和 STATA 12.0 软件分析提取的数据。进行亚组分析和荟萃回归分析以寻找潜在的异质性来源。
纳入了 12 项研究,共 1145 名参与者。与正常妊娠相比,PE 孕妇的血液 HMGB1 水平显著升高(SMD=1.34,95%CI:0.72-1.95,p<0.0001)。同样,使用 Western blot(MD=0.37,95%CI:0.27-0.47,p<0.00001)或免疫组织化学(OR=6.36,95%CI:1.48-27.25,p=0.01)检测,PE 患者的胎盘 HMGB1 表达也高于正常对照组。此外,血液 HMGB1 水平与 PE 的严重程度呈正相关,重度 PE 患者的血液 HMGB1 水平高于轻度 PE 患者(SMD=3.35,95%CI:0.63-6.06,p=0.02)。亚组分析表明,血液 HMGB1 与亚洲组的 PE 密切相关,但与欧洲组无关。
PE 患者的血液和胎盘 HMGB1 水平均显著升高,且血液 HMGB1 水平升高提示疾病状况更严重,表明 HMGB1 水平升高与 PE 的发病风险相关。